Better Understand the Symptoms and Care Options of IBS and CIC

Course Overview

Nearly 1 in 10 adults and nearly 15% of children suffer the fluctuating symptom patterns of abdominal pain, disturbed defecation, and extra-intestinal symptoms associated with Irritable Bowel Syndrome. IBS-C and IBS-D represents a significant health burden owing to direct medical costs and indirect costs. Misdiagnosis and under treatment leads to waste and unnecessary patient suffering. Diet, stress, and other sociocultural factors can influence prevalence, health care–seeking behavior, symptoms, and treatment response. Regrettably, practicing physicians and mid-level providers do not always fully understand the pathways and treatment options available now and those in development.

Topics to be covered in this interactive seminar include:

  • An overview of Irritable Bowel Syndrome (IBS) and Chronic Idiopathic Constipation (CIC)
  • Epidemiology - Clinical Presentation and Treating Adults & Children
  • Pathogenesis of IBS-D, IBS-C and CIC
  • An updated classification system for IBS, the Rome IV diagnostic criteria
  • Management of IBS and CIC Patients through Dietary approaches, Anti-spasmodic therapies and Behavioral Approaches
  • Recently approved therapeutic agents for IBS-D, IBS-C and CIC
  • Patient care management for Advanced Discussion -practice clinicians and specialty nurses


The program is available as real-time, streaming webinar with an interactive Q/A with the faculty

Strategy


CDC-Recommended COVID-19 Precautions will be Implemented at All Live Seminars



Registration Fees: There is no charge to participate in these programs, but pre-registration is required

This program has been developed for:

Gastroenterologists
Internists
Family Physicians
Advanced-Practice Providers and Nurse Specialists
Clinical Pharmacists

For more information:

This course is supported in part by an educational grant from Salix - a division of Bausch Health in accordance with ACCME accreditation Standards of Commercial Support.

Designation Statements

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates Emerging Therapies for PBC, NASH, ESLD and HCC as a live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™; designates Viral Hepatitis Training and Treatment Update seminar for 7.0 AMA PRA Category 1 Credit(s)™; and designates the Symptoms and Care Options of IBS and CIC seminar for 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - Emerging Therapies for PBC, NASH, ESLD and HCC has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Viral Hepatitis Training and Treatment Update seminar has been approved for 8.4 Continuing Education Credits through the University of Louisville Hospital, provider number 4-0068-7-20-1169. The Symptoms and Care Options of IBS and CIC seminar has been approved for 1.2 Continuing Education Credits through the University of Louisville Hospital, provider number 4-0068-7-20-1170.

For more information contact:

University of Louisville Office of CME and Professional Development
501 E. Broadway Su 370
Louisville, KY 40202

Phone: (502) 852-5329
Email: cmepd@louisville.edu

Top